NCT00070733 is a Phase 3 clinical trial of testosterone enanthate in Sex Disorders, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

What drugs are being tested in NCT00070733?

Interventions in NCT00070733: testosterone enanthate, duastride.

What condition does NCT00070733 study?

NCT00070733 studies Sex Disorders.

Is NCT00070733 still recruiting?

NCT00070733 is currently status unknown. Last updated 4 November 2005.

Last reviewed 2005-11-04 · How we verify

NCT00070733

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Role of 5-Alpha Reductase in Mediating Testosterone Actions

Status unknown Phase 3 Last updated 4 November 2005

What this trial tests

Phase 3 trial testing testosterone enanthate in Sex Disorders in 184 participants. Status unknown.

Timeline

1 August 2003

1 June 2005

Quick facts

Lead sponsor	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	184
Start date	1 August 2003
Estimated completion	1 June 2005
Sites	1 location across United States

Drugs / interventions tested

testosterone enanthate — full drug profile →
duastride — full drug profile →

Conditions studied

Sex Disorders — all drugs for Sex Disorders →

Sponsor

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Who can join

Adults 21 to 40, male only, with Sex Disorders. Healthy volunteers can join.

Sponsor's own description

The enzyme 5-alpha reductase is present in small amounts in muscle and converts testosterone to dihydrotestosterone (DHT). Testosterone affects lean body tissue, muscle size, muscle strength, and sexual function in men. This study will evaluate how 5-alpha reductase influences the effects of testosterone in young healthy men.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) trials

Trials by the same sponsor.

NCT07502586 — Turner Syndrome: Genetic Considerations · recruiting
NCT07357701 — Identifying Genome Variants in Non-Obstructive Azoospermia (NOA) or Primary Ovarian Insufficiency (POI) · recruiting
NCT06851754 — Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency · Phase 3 · recruiting
NCT05548881 — Implications of Maternal 45,X Mosaicism as a Secondary Genomic Finding Following Cell-Free DNA Sequencing During Pregnan · withdrawn
NCT06749366 — Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00070733 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Last refreshed: 4 November 2005

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00070733.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing